Citius Oncology Inc (NASDAQ: CTOR) has seen a decline in its stock price by -6.47 in relation to its previous close of 1.39. However, the company has experienced a 1.56% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-17 that CRANFORD, N.J., June 17, 2025 /PRNewswire/ — Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), are nearing completion.
Is It Worth Investing in Citius Oncology Inc (NASDAQ: CTOR) Right Now?
Additionally, the 36-month beta value for CTOR is 0.01. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTOR is 3.52M and currently, short sellers hold a 0.72% ratio of that float. The average trading volume of CTOR on June 17, 2025 was 1.48M shares.
CTOR’s Market Performance
The stock of Citius Oncology Inc (CTOR) has seen a 1.56% increase in the past week, with a 43.82% rise in the past month, and a 127.63% gain in the past quarter. The volatility ratio for the week is 6.68%, and the volatility levels for the past 30 days are at 4.83% for CTOR. The simple moving average for the last 20 days is 21.02% for CTOR stock, with a simple moving average of 17.96% for the last 200 days.
Analysts’ Opinion of CTOR
Many brokerage firms have already submitted their reports for CTOR stocks, with Maxim Group repeating the rating for CTOR by listing it as a “Buy.” The predicted price for CTOR in the upcoming period, according to Maxim Group is $3 based on the research report published on November 27, 2024 of the previous year 2024.
CTOR Trading at 45.22% from the 50-Day Moving Average
After a stumble in the market that brought CTOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.35% of loss for the given period.
Stock Fundamentals for CTOR
Based on Citius Oncology Inc (CTOR), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1.
Currently, EBITDA for the company is -20.57 million with net debt to EBITDA at -0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.36.
Conclusion
In conclusion, Citius Oncology Inc (CTOR) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
